IACP Sends Letter to The Washington Post Editor
02/27/13 -- On February 21, 2013, The Washington Post printed an article, "Pharmacy Trade Group Shifts Position on FDA Oversight."
Please be aware that this article alleging that IACP is now supporting FDA oversight of compounding pharmacy, is neither accurate nor reflective of the complete story. In fact, IACP gave the reporter very specific written statements which were subsequently given a spin by the journalist.
The following is the exact language we gave to the reporter:
1) IACP is supportive of a discussion about the creation of a category of non-traditional manufacturing. A formal position has not yet been taken by the IACP nor, to our knowledge, by any other pharmacy organization. This is a concept that we believe needs to be reviewed and discussed in the public arena.
2) For this group of non-traditional manufacturers, if they are manufacturers, we would expect that the FDA would regulate them. The FDA would have to determine if the same criteria would be applied to this category as is applied to traditional manufacturers. Any compounding pharmacy – not a manufacturer, traditional or non-traditional – should continue to be regulated and overseen by state boards of pharmacy.
In short, IACP supports a policy conversation about regulating manufacturing. We have not endorsed or supported a specific program, design, concept or anything else. Strictly a discussion. That is consistent with IACP's statements to Congress and state regulatory authorities.
IACP sent a Letter to The Washington Post Editor to correct the statements made in the article, and to reinforce the information we had originally submitted to the reporter.
Click here for The Washington Post article, February 21, 2013.
Click here to read IACP's Letter to the Editor sent to The Washington Post.
Please email IACP if you have any questions regarding this article or our response to The Washington Post.